| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Appendix 4G and Corporate Governance Statement
|
29 Aug 2025 12:37PM |
$1.140 |
$0.520 |
fallen by
54.39%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Appendix 4E and Annual Report
|
29 Aug 2025 12:32PM |
$1.140 |
$0.520 |
fallen by
54.39%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- OncoSil Medical Ltd's financial report covers the fiscal year ending 30 June 2025.
- The company reported a total comprehensive loss of $15,084,881 for the year.
- Equity consists of issued capital, reserves, and accumulated losses, totaling $3,103,521.
- There were no dividends declared during the financial year.
- Significant share and option transactions included consolidation and issuance of new shares and options.
- Performance rights and share-based payments are key components of employee and executive compensation.
- The company's strategic focus remains on the commercialization of OncoSilâ„¢, a targeted brachytherapy product.
- Significant stakeholders include BNP Paribas Noms Pty Ltd and HSBC Custody Nominees (Australia) Limited.
- The company's issued capital as of 30 June 2025 is 14,220,777 shares, valued at $96,425,110.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Application for quotation of securities - OSL
|
22 Aug 2025 10:30AM |
$1.090 |
$0.520 |
fallen by
52.29%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Investor Webinar Presentation
|
7 Aug 2025 10:14AM |
$1.085 |
$0.520 |
fallen by
52.07%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Investor Webinar Invitation
|
7 Aug 2025 10:06AM |
$1.085 |
$0.520 |
fallen by
52.07%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Jul 2025 5:41PM |
$1.130 |
$0.520 |
fallen by
53.98%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Oncosil Medical Limited (OSL) provided its quarterly activities report and Appendix 4C cash flow report for the quarter ended 31 March 2024.
- During the quarter, OSL continued commercial rollout activities for the OncoSilâ„¢ device in existing European markets, including the UK, Spain, Italy, and Germany.
- The company achieved important procedural milestones, with the first patient treated in the UK under an NHS-funded procedure and continued recruitment in the PanCO clinical study.
- OSL advanced reimbursement and hospital adoption processes in targeted European and Asia-Pacific markets, with progress in Spain, Germany, and Australia.
- Revenue for the quarter was $267,000, mostly derived from device sales in Europe.
- Net operating cash outflows for the quarter were $2.41 million, mainly attributed to ongoing commercial, clinical, and regulatory activities.
- OSL reported a cash balance of $8.47 million at the end of the reporting period.
- The company is actively focused on enhancing clinician awareness, securing reimbursement, and expanding hospital adoption of the OncoSilâ„¢ device.
- Key strategic and operational priorities include driving growth in core markets, expanding clinical evidence, and progressing towards broader reimbursement approvals.
- No payments were made to related parties except for $155,000 paid to directors as salary and fees.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Appointment and Resignation of Company Secretary
|
23 Jul 2025 5:40PM |
$1.160 |
$0.520 |
fallen by
55.17%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Completion of Recruitment in TRIPP-FFX Clinical Trial
|
23 Jul 2025 8:27AM |
$1.185 |
$0.520 |
fallen by
56.12%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Oncosil Medical Limited has completed recruitment for the TRIPP-FFX clinical trial.
- The TRIPP-FFX trial investigates the OncoSilâ„¢ device in combination with FOLFIRINOX for locally advanced pancreatic cancer.
- A total of 71 patients have been enrolled in the study.
- Clinical sites for the trial are located internationally.
- Completion of recruitment marks a major milestone in the company’s clinical program.
- The next steps involve data analysis and preparation for regulatory and commercial processes.
- The OncoSilâ„¢ device is designed to deliver targeted radiation directly to pancreatic tumors.
- The company acknowledges the contribution of patients, investigators, and clinical teams.
- Further updates will be provided as trial data becomes available.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Change in substantial holding from SOL
|
15 Jul 2025 5:07PM |
$1.110 |
$0.520 |
fallen by
53.15%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Change in substantial holding from PCG
|
15 Jul 2025 1:44PM |
$1.110 |
$0.520 |
fallen by
53.15%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Change in substantial shareholding from AEF
|
15 Jul 2025 12:52PM |
$1.120 |
$0.520 |
fallen by
53.57%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Application for quotation of securities - OSL
|
15 Jul 2025 8:36AM |
$1.100 |
$0.520 |
fallen by
52.73%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Final Director's Interest Notice
|
11 Jul 2025 2:00PM |
$1.110 |
$0.520 |
fallen by
53.15%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Initial Director's Interest Notice
|
11 Jul 2025 1:59PM |
$1.120 |
$0.520 |
fallen by
53.57%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
OSLOD Options Range of Units and Top 20 Holders
|
11 Jul 2025 10:45AM |
$1.110 |
$0.520 |
fallen by
53.15%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Application for quotation of securities - OSL
|
11 Jul 2025 10:45AM |
$1.110 |
$0.520 |
fallen by
53.15%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Application for quotation of securities - OSL
|
11 Jul 2025 10:44AM |
$1.110 |
$0.520 |
fallen by
53.15%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
OncoSil announces appointment of Non-Executive Director
|
11 Jul 2025 9:44AM |
$1.250 |
$0.520 |
fallen by
58.40%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Proposed issue of securities - OSL
|
9 Jul 2025 1:48PM |
$1.230 |
$0.520 |
fallen by
57.72%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Update - Proposed issue of securities - OSL
|
9 Jul 2025 12:35PM |
$1.230 |
$0.520 |
fallen by
57.72%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Update - Proposed issue of securities - OSL
|
9 Jul 2025 12:29PM |
$1.230 |
$0.520 |
fallen by
57.72%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Results of Meeting
|
8 Jul 2025 1:03PM |
$1.255 |
$0.520 |
fallen by
58.57%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
OSL completes $2 million Share Purchase Plan
|
7 Jul 2025 5:06PM |
$1.175 |
$0.520 |
fallen by
55.74%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Completion of Recruitment in PANCOSIL Study
|
4 Jul 2025 8:24AM |
$1.195 |
$0.520 |
fallen by
56.49%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Oncosil Medical Limited completed recruitment for the PANCOSIL study targeting pancreatic cancer.
- 180 patients with locally advanced pancreatic cancer were enrolled across various international sites.
- The PANCOSIL study investigates OncoSil device in combination with chemotherapy.
- Recruitment completion is a significant milestone for the company's clinical development.
- Top-line study results are expected within 12 months.
- Results may support further regulatory submissions and market expansion for OncoSil.
- The study underscores Oncosil’s commitment to innovation in pancreatic cancer therapy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$16 |
Becoming a substantial shareholder from AEF
|
26 Jun 2025 11:38AM |
$1.105 |
$0.520 |
fallen by
52.94%
|
|